{"name":"Yung Shin Pharm. Ind. Co., Ltd.","slug":"yung-shin-pharm-ind-co-ltd","ticker":"","exchange":"","domain":"","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Other","slug":"other","revenue":0,"percentOfTotal":0,"drugCount":7,"colorKey":"oncology","drugs":[{"name":"Esomelone","genericName":"Esomelone","slug":"esomelone","indication":"Other","status":"marketed"},{"name":"Mepem","genericName":"Mepem","slug":"mepem","indication":"Other","status":"marketed"},{"name":"Entigin Film Coated Tablet 0.5mg","genericName":"Entigin Film Coated Tablet 0.5mg","slug":"entigin-film-coated-tablet-0-5mg","indication":"Other","status":"marketed"},{"name":"Meropem","genericName":"Meropem","slug":"meropem","indication":"Other","status":"marketed"},{"name":"Nolbaxol","genericName":"Nolbaxol","slug":"nolbaxol","indication":"Other","status":"phase_2"},{"name":"Vaway","genericName":"Vaway","slug":"vaway","indication":"Other","status":"marketed"},{"name":"valacyclovir hydrocholoride","genericName":"valacyclovir hydrocholoride","slug":"valacyclovir-hydrocholoride","indication":"Other","status":"marketed"}]},{"name":"Infectious Disease","slug":"infectious-disease","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"immunology","drugs":[{"name":"cefoperazone sodium and sulbactam sodium","genericName":"cefoperazone sodium and sulbactam sodium","slug":"cefoperazone-sodium-and-sulbactam-sodium","indication":"Bacterial infections caused by susceptible organisms (respiratory tract infections, urinary tract infections, intra-abdominal infections, skin and soft tissue infections)","status":"marketed"}]}],"pipeline":[{"name":"Esomelone","genericName":"Esomelone","slug":"esomelone","phase":"marketed","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"Mepem","genericName":"Mepem","slug":"mepem","phase":"marketed","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"cefoperazone sodium and sulbactam sodium","genericName":"cefoperazone sodium and sulbactam sodium","slug":"cefoperazone-sodium-and-sulbactam-sodium","phase":"marketed","mechanism":"Cefoperazone sodium inhibits bacterial cell wall synthesis while sulbactam sodium protects the antibiotic from beta-lactamase degradation, together providing broad-spectrum bactericidal activity.","indications":["Bacterial infections caused by susceptible organisms (respiratory tract infections, urinary tract infections, intra-abdominal infections, skin and soft tissue infections)","Polymicrobial infections including beta-lactamase-producing strains"],"catalyst":""},{"name":"Entigin Film Coated Tablet 0.5mg","genericName":"Entigin Film Coated Tablet 0.5mg","slug":"entigin-film-coated-tablet-0-5mg","phase":"marketed","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"Meropem","genericName":"Meropem","slug":"meropem","phase":"marketed","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"Nolbaxol","genericName":"Nolbaxol","slug":"nolbaxol","phase":"phase_2","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"Vaway","genericName":"Vaway","slug":"vaway","phase":"marketed","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"valacyclovir hydrocholoride","genericName":"valacyclovir hydrocholoride","slug":"valacyclovir-hydrocholoride","phase":"marketed","mechanism":"Small molecule","indications":[],"catalyst":""}],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMi_wFBVV95cUxQcWJPM1VBVUtZMklibGJ0UXMxZmJUU2EtTXF5c3BqV2NNTlF2VTY3aEcwTG9INi00QUJHaTlTbUNZTU1Fd0FubjFzTXk5VnpFYjF3QXZkZWw5a0xGdUZUNXZnYjdDb0hRZlphbE1sbXBENTF5S2tkQVBLUFc2M3c3R3FUY1BQWnlSUi03N1R5cmtaOEpMd0hFRUo3UmhCeG56YVdWZDR2VXdEN29ZeWw1SERRMjYtZV8xM3hvUjBCTzZCbkZ3UkJhUVp5ZDVmYnlWbnVzTUlkLWh0cmtGVHU1VlJLY1h0WWVXcUpTc0RpcDR3OTZNbm53blpfQm9Nems?oc=5","date":"2026-04-07","type":"pipeline","source":"Barchart.com","summary":"Herpes Zoster Treatment Market Size in the 7MM is projected to increase at a significantly CAGR by 2036, estimates DelveInsight - Barchart.com","headline":"Herpes Zoster Treatment Market Size in the 7MM is projected to increase at a significantly CAGR by 2036, estimates Delve","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMilAJBVV95cUxNaC0xWjQxemp6SjQ4ZkFIRXZmTk95R1N6ZVdNajZyNkhsM042NUdqRnhsMUpfZ2JxVXZCek9RRkNjQ3FCZGN6NENnSWk3UDRYMW1UUDdvdTBDRHc1b0s1WURGak8xa3dmWjViYk5pT1N4amRYdDlEWVFkNmFJekE1ZVpKamZfeGk0WG9pb09BWFFLb1lwQVlxaFhoVl9tVmVnYzFEYXBualdZazROeEtVTFNXTzRPZ1VQb1pyRnJPX0NvUWRZTXI1U3VWMEhVMDhfcndrYm1qdTd0TFB3bjhrcXFZd2ZVNXo5ZHpCUUFZRzBUUWhOVGNhamVuX2VxRDh6STdHOTRfWGVaV1psUnpwTnJPLU0?oc=5","date":"2026-01-19","type":"pipeline","source":"PR Newswire","summary":"Underactive Bladder Syndrome Market to Observe Stunning Growth at a CAGR of 22.1% During the Forecast Period (2025-2034) | DelveInsight - PR Newswire","headline":"Underactive Bladder Syndrome Market to Observe Stunning Growth at a CAGR of 22.1% During the Forecast Period (2025-2034)","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMihAFBVV95cUxNZC02eHR1SGpVMnVNVUt4cHJYT0dqN2RzU2J5NkU0ZmwtVVByWGhBM0h3Si1aRlFGQkdGSm04ZV9VVHdOTTY2YzJVMW03NUF2dFZTWHB1MHBtQ1N6UjBPbDZTbzZrNDhpOTFVUUFnSHFTUVNfWHJzQWxnLW1rTWFPcXVWdjA?oc=5","date":"2022-06-27","type":"pipeline","source":"Market.us","summary":"Asia-Pacific Active Pharmaceutical Ingredient Market CAGR Of 8.7% - Market.us","headline":"Asia-Pacific Active Pharmaceutical Ingredient Market CAGR Of 8.7%","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiogFBVV95cUxPZnh2cDBVR0pvb1dJbUxnT0k2SFk2YVBpMlBRRzBlb3pMTHFMZ20wWjlkYlU2LWJtZGN5LXBCTFhhTGtBR0V4Tkk0d0FlQ0lNeU5zdGNJTTl3cWlteHR5WjZ4ZjZOdTM0WmhwOXdjNVo0NXRhalJta0V0QnlWSmxzM2NodnFxaV9mUFdfNDFnR3dRVW5QZEFCMnd4XzlpTy02aVHSAagBQVVfeXFMT0hGZ0ZMSEQ1TXlKRFU0c2l3blFUTnQ0Q3RMRmY2OGpqRE9Qei14TF9Fd0xjM0o3OWV2X3VQcjVBdVQ1RlE4Vmp0TVA3bGdMUkNCYnJDa3lqQ3ozWEN1emtQUFN6RDdTZDI3N0J5MTZMZ1BNQVMyMUhqeU1KQncyQ3pxcjljZHVKMHc3UVlDZXpLVGctY2NOYzFPT1FaY3FHN28tZGJob3ZD?oc=5","date":"2021-05-28","type":"deal","source":"Indian Pharma Post","summary":"TLC partners Strides to launch Mucormycosis drug in India - Indian Pharma Post","headline":"TLC partners Strides to launch Mucormycosis drug in India","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiX0FVX3lxTFBLcG53OXNtdzNBNE5LVTBHVjRVV1A0UFpyUUpyRmdCbFJIT2tjYmpvZEx1SEhROG9lTXpzSC12c09ETW9BTVFvVl9ubFJmbjZPMWNwOVlUREg1Z09WRUJz?oc=5","date":"2019-04-26","type":"pipeline","source":"Mindanao State University - Iligan Institute of Technology","summary":"Benchmarking Activities of VCRE Bornales and PRISM Director Uy in Malaysia - Mindanao State University - Iligan Institute of Technology","headline":"Benchmarking Activities of VCRE Bornales and PRISM Director Uy in Malaysia - Mindanao State University","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMirgFBVV95cUxOdmZlN2FoYjk2UlBZNG9JdW9uZENla095VUdGamZtQ0lNelVEOG55UnAtMERuME1GYjVRcFhkQ21Pc0ZobHczUXNVR0p3MldyZjhjSHB4ekJWUEpDX01keUh3N3dKUW9ILWhGTDN0OWhhNGhQZ0xyaHlSc05hbVBndWxFZDhMSktkR1Zla0kzZ3YzRnFtcHpYNXFUX1RoSDdSSmdmX2hJQmR1ckdnb3c?oc=5","date":"2016-02-10","type":"regulatory","source":"RAPS.org","summary":"US FDA Inspections in China: An Analysis of Form 483s from 2015 - RAPS.org","headline":"US FDA Inspections in China: An Analysis of Form 483s from 2015","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi6AFBVV95cUxPWm94LVJnRERucTQ1dGpuTk5KaGNnNThwemlxUHpnbXhBWEJHV1RPaUZRVHdoRl9ZMVpXbFFDUmF0QzYtVmdYb0k1eTJqSlZtTl90b0dNYWg4Umg0VFFHQ3R5WWFxejU5Rl9CU3p5WnpLa1NVV1YyUGd5MWZpVWV0NDFVaDItUTNLaFNNTjRaRzdwNDRsM0VTVS03bG1YaTlCdGtpT2ItUGJndkZyWURuUzBBcnFLRWVBT2ttRVVab3JUMW12cUJBTHY1cTM5bVNUMklGRVVJNjJPMjBCUWtIWVRkUWt1ZHVS?oc=5","date":"2012-10-15","type":"deal","source":"Technology Networks","summary":"Industry Leaders to Meet in Taiwan for Clinical Outsourcing and Collaboration Opportunities - Technology Networks","headline":"Industry Leaders to Meet in Taiwan for Clinical Outsourcing and Collaboration Opportunities","sentiment":"neutral"}],"patents":[],"drugCount":8,"phaseCounts":{"marketed":7,"phase_2":1},"enrichmentLevel":2,"visitCount":2,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}